{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:24:16Z","timestamp":1792985056031,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johnson & Johnson Medical (Shanghai) Ltd","award":["DPS-201502"],"award-info":[{"award-number":["DPS-201502"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Trauma Emerg Surg"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate whether the 24-weeks postoperative fracture union rate for the investigational TFNA intramedullary nail was non-inferior compared to the control product PFNA-II.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study was a prospective, randomized, single-blind, noninferiority dual-arm study drawing from 9 trauma centers across China, between November 2018 and September 2020, with follow-up measurements at 24\u00a0weeks after internal fixation. The full analysis data set (FAS [Intent-to-Treat]) was analyzed and is summarized here. The primary outcome was fracture union rate, a composite score combining clinical and radiographic assessment. Secondary endpoints comprised (a) clinical outcomes including (1) SF-12, (2) Harris Hip, and (3) EQ-5D Scores, (b) radiographic incidence of complications such as loosening or cut-out requiring revision, (c) revision rates, (d) reoperation rates, and (e) adverse events, including 24-weeks revision and reoperation rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Both TFNA and PFNA-II group fracture healing rates were 100% at 24\u00a0weeks; TFNA was therefore shown to be non-inferior to PFNA-II. With baseline data matched in all parameters except age in both the TFNA and PFNA-II groups, comparisons of union rates, SF-12, Harris Hip, and EQ-5D Scores yielded <jats:italic>p<\/jats:italic> values\u2009&gt;\u20090.05 indicating no significant difference between the two groups, further supporting the noninferiority of TFNA. In both groups, revision and re-operation rates were 0, and the incidences of serious adverse events were 19.4% and 17.4%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In terms of fracture union rate at 24\u00a0weeks, the DePuy Synthes Trochanteric Fixation Nail Advanced (TFNA) was not inferior to the marketed Proximal Femoral Nail Antirotation (PFNA-II) device produced by the same manufacturer. Secondary and safety outcomes showed no significant differences between the two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Registration<\/jats:title>\n                <jats:p>Registration was completed at ClinicalTrials.gov NCT03635320.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00068-023-02231-x","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T14:18:32Z","timestamp":1676297912000},"page":"1561-1575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prospective randomized multicenter noninferiority clinical trial evaluating the use of TFN-advancedTM proximal femoral nailing system (TFNA) for the treatment of proximal femur fracture in a Chinese population"],"prefix":"10.1007","volume":"49","clinical-trial-number":[{"clinical-trial-number":"nct03635320","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lidan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiugen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peifu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frankie K. L.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hughson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Blauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rosner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charisse","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"2231_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5704\/MOJ.1107.001","volume":"5","author":"W Loo","year":"2011","unstructured":"Loo W, Loh S, Lee H. Review of Proximal Nail Antirotation (PFNA) and PFNA-2\u2013our local experience. Malaysian Orthop J. 2011;5:1\u20135.","journal-title":"Malaysian Orthop J"},{"key":"2231_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clinbiomech.2008.09.005","volume":"24","author":"M Windolf","year":"2009","unstructured":"Windolf M, Muths R, Braunstein V, Gueorguiev B, Hanni M, Schwieger K. Quantification of cancellous bone-compaction due to DHS Blade insertion and influence upon cut-out resistance. Clin Biomech (Bristol, Avon). 2009;24:53\u20138.","journal-title":"Clin Biomech (Bristol, Avon)"},{"key":"2231_CR3","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.295.10.1172","volume":"295","author":"PC G\u00f8tzsche","year":"2006","unstructured":"G\u00f8tzsche PC. Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA. 2006;295:1172\u20134.","journal-title":"JAMA"},{"key":"2231_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bbmt.2008.10.004","volume":"15","author":"G Tunes da Silva","year":"2009","unstructured":"Tunes da Silva G, Logan BR, Klein JP. Methods for equivalence and noninferiority testing. Biol Blood Marrow Transplant. 2009;15:120\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2231_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1592\/phco.31.9.833","volume":"31","author":"KJ Suda","year":"2011","unstructured":"Suda KJ, Hurley AM, McKibbin T, Motl Moroney SE. Publication of noninferiority clinical trials: changes over a 20-year interval. Pharmacotherapy. 2011;31:833\u20139.","journal-title":"Pharmacotherapy"},{"key":"2231_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1161\/CIRCULATIONAHA.119.040214","volume":"140","author":"B Bikdeli","year":"2019","unstructured":"Bikdeli B, Welsh JW, Akram Y, Punnanithinont N, Lee I, Desai NR, et al. Noninferiority designed cardiovascular trials in highest-impact journals. Circulation. 2019;140:379\u201389.","journal-title":"Circulation"},{"key":"2231_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/CVM-1-1-019","volume":"1","author":"SM Snapinn","year":"2000","unstructured":"Snapinn SM. Noninferiority trials. Curr Control Trials Cardiovasc Med. 2000;1:19\u201321.","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"2231_CR8","volume-title":"AO surgery reference","author":"F Raaymakers","year":"2010","unstructured":"Raaymakers F, Schatzker H, Hensen M, Pesantez RF. AO surgery reference. 2nd ed. AO; 2010.","edition":"2"},{"key":"2231_CR9","doi-asserted-by":"publisher","DOI":"10.1201\/EBK1439808184","volume-title":"Testing statistical hypotheses of equivalence and noninferiority","author":"S Wellek","year":"2010","unstructured":"Wellek S. Testing statistical hypotheses of equivalence and noninferiority. 2nd ed. London: Chapman & Hall\/CRC; 2010.","edition":"2"},{"key":"2231_CR10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","volume":"17","author":"RG Newcombe","year":"1998","unstructured":"Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857\u201372.","journal-title":"Stat Med"},{"key":"2231_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003180","volume":"17","author":"C Zhang","year":"2020","unstructured":"Zhang C, Feng J, Wang S, Gao P, Xu L, Zhu J, et al. Incidence of and trends in hip fracture among adults in urban China: a nationwide retrospective cohort study. PLoS Med. 2020;17: e1003180.","journal-title":"PLoS Med"},{"key":"2231_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.12671\/jkfs.2020.33.4.189","volume":"33","author":"JY Yoon","year":"2020","unstructured":"Yoon JY, Kim JW. Treatment of proximal femur fracture with a newly designed nail: trochanteric fixation nail-advanced (TFNA). J Korean Fract Soc. 2020;33:189\u201395.","journal-title":"J Korean Fract Soc"},{"key":"2231_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2151459320936444","volume":"11","author":"T Matsumura","year":"2020","unstructured":"Matsumura T, Takahashi T, Nakashima M, Nibe Y, Takeshita K. Clinical outcome of mid-length proximal femoral nail for patients with trochanteric hip fractures: preliminary investigation in a Japanese cohort of patients more than 70 years old. Geriatr Orthop Surg Rehabil. 2020;11:1\u20137.","journal-title":"Geriatr Orthop Surg Rehabil"},{"key":"2231_CR14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s43465-020-00219-y","volume":"54","author":"JDC Unsay","year":"2020","unstructured":"Unsay JDC, Huat ICT, Kee EKB. Early experience with the trochanteric fixation nail-advanced (TFN-A): a descriptive review of thirty-four cases from a single center. Indian J Orthop. 2020;54:246\u201353.","journal-title":"Indian J Orthop"},{"key":"2231_CR15","doi-asserted-by":"publisher","first-page":"804","DOI":"10.2106\/JBJS.18.00997","volume":"101","author":"A Lambers","year":"2019","unstructured":"Lambers A, Rieger B, Kop A, D\u2019Alessandro P, Yates P. Implant fracture analysis of the TFNA Proximal Femoral Nail. J Bone Joint Surg Am. 2019;101:804\u201311.","journal-title":"J Bone Joint Surg Am"},{"key":"2231_CR16","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.injury.2014.06.002","volume":"45","author":"T Sawaguchi","year":"2014","unstructured":"Sawaguchi T, Sakagoshi D, Shima Y, Ito T, Goldhahn S. Do design adaptations of a trochanteric nail make sense for Asian patients? Results of a multicenter study of the PFNA-II in Japan. Injury. 2014;45:1624\u201331.","journal-title":"Injury"},{"issue":"17","key":"2231_CR17","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.2106\/JBJS.20.02002","volume":"103","author":"A Wallace","year":"2021","unstructured":"Wallace A, Amis J, Cafri G, Coplan P, Wood J. Comparative safety of the TFN-ADVANCED Proximal Femoral Nailing System: findings from a U.S. Health-Care Database. J Bone Joint Surg Am. 2021;103(17):1637\u201345.","journal-title":"J Bone Joint Surg Am"},{"key":"2231_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026685","volume":"9","author":"KC Deere","year":"2019","unstructured":"Deere KC, Whitehouse MR, Porter M, Blom AW, Sayers A. Assessing the non-inferiority of prosthesis constructs used in hip replacement using data from the National Joint Registry of England, Wales, Northern Ireland and the Isle of Man: a benchmarking study. BMJ Open. 2019;9: e026685.","journal-title":"BMJ Open"},{"key":"2231_CR19","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jhep.2007.02.015","volume":"46","author":"E Christensen","year":"2007","unstructured":"Christensen E. Methodology of superiority vs. equivalence trials and non-inferiority trials. J Hepatol. 2007;46:947\u201354.","journal-title":"J Hepatol"},{"key":"2231_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1046\/j.1365-2125.2001.01397-3.x","volume":"52","author":"Committee for Proprietary Medicinal Products","year":"2001","unstructured":"Committee for Proprietary Medicinal Products. Points to consider on switching between superiority and non-inferiority. Br J Clin Pharmacol. 2001;52:223\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"2231_CR21","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S0140-6736(99)07403-6","volume":"354","author":"F Van De Werf","year":"1999","unstructured":"Assessment of the Safety, Efficacy of a New Thrombolytic Investigators, Van De Werf F, Adgey J, Ardissino D, Armstrong PW, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double- blind randomised trial. Lancet. 1999;354:716\u201322.","journal-title":"Lancet"},{"key":"2231_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13063-017-2024-2","volume":"18","author":"J Ganju","year":"2017","unstructured":"Ganju J, Rom D. Non-inferiority versus superiority drug claims: the (not so) subtle distinction. Trials. 2017;18:278.","journal-title":"Trials"},{"key":"2231_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10195-016-0405-z","volume":"17","author":"J Dunn","year":"2016","unstructured":"Dunn J, Kusnezov N, Bader J, Waterman BR, Orr J, Belmont PJ. Long versus short cephalomedullary nail for trochanteric femur fractures (OTA 31\u2013A1, A2 and A3): a systematic review. J Orthop Traumatol. 2016;17:361\u20137.","journal-title":"J Orthop Traumatol"},{"key":"2231_CR24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.otsr.2017.04.003","volume":"103","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Zhang S, Wang S, Zhang H, Zhang W, Liu P, et al. Long and short intramedullary nails for fixation of intertrochanteric femur fractures (OTA 31\u2013A1, A2 and A3): a systematic review and meta-analysis. Orthop Traumatol Surg Res. 2017;103:685\u201390.","journal-title":"Orthop Traumatol Surg Res"},{"issue":"10","key":"2231_CR25","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/BOT.0000000000001553","volume":"33","author":"SF Shannon","year":"2019","unstructured":"Shannon SF, Yuan BJ, Cross WW, Barlow JD, Torchia ME, Holte PK, Sens SA. Short versus long cephalomedullary nails for pertrochanteric hip fractures: a randomized prospective study. J Orthop Trauma. 2019;33(10):480\u20136.","journal-title":"J Orthop Trauma"}],"container-title":["European Journal of Trauma and Emergency Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00068-023-02231-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00068-023-02231-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00068-023-02231-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T08:09:02Z","timestamp":1685434142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00068-023-02231-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2231"],"URL":"https:\/\/doi.org\/10.1007\/s00068-023-02231-x","relation":{},"ISSN":["1863-9933","1863-9941"],"issn-type":[{"value":"1863-9933","type":"print"},{"value":"1863-9941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We declare that we except for employees of Johnson&Johnson do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved on 11th April, 2016 in the leading site, and it was also approved in all other sites.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All subjects have agreed to join the study and they have signed on the informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}